Eli Lilly is expanding type 2 diabetes treatment options with Onswik, a once-weekly basal insulin recently approved by the FDA. Designed to provide steady basal insulin levels for seven days, Onswik reduces injection frequency compared to traditional daily basal insulin. Its approval is supported by the QWINT Phase 3 program, which studied more than 3,400 adults and found comparable A1C reductions to daily insulin glargine or insulin degludec across the trials.
The weekly format addresses the treatment burden associated with frequent injections, potentially offering greater flexibility for adults managing type 2 diabetes. For Lilly, Onswik expands its established insulin portfolio with a differentiated dosing schedule as diabetes treatment becomes increasingly focused on convenience and adherence. The upcoming U.S. availability of two KwikPen concentrations also gives healthcare providers additional prescribing options while positioning Lilly to compete within the emerging market for reduced-frequency insulin therapies.
Image Credit: Eli Lilly and Company
What's Driving This Trend
- Weekly Insulin Dosing
- Longer-acting basal formulations are reshaping diabetes care by reducing injection frequency and opening space for adherence-focused medication design.
- Convenience-led Chronic Care
- Treatment models centered on lower patient burden are creating new value in chronic disease management through simplified routines and flexible dosing.
- Differentiated Delivery Formats
- Multiple pen concentrations and reduced-frequency regimens are expanding personalization in injectable therapies while supporting more tailored prescribing decisions.
Who This Affects Most
- Diabetes Care
- The shift toward once-weekly insulin introduces competitive potential for therapies that improve adherence without compromising glycemic outcomes.
- Pharmaceuticals
- Established drug portfolios are gaining renewed differentiation as companies reformulate or repackage therapies around convenience and patient experience.
- Medical Devices
- Insulin pen innovation is becoming more strategic as delivery systems adapt to longer-acting medications and varied dosing requirements.
